NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS), a leader in the emerging cellular therapy industry, is issuing this press release to clarify for shareholders that NeoStem is not engaged in a new financing. The registration statement filed today is merely a renewal of an outstanding registration statement covering the issuance of shares underlying warrants (exercisable at per share prices of $1.43 and greater) that were issued 3 years ago and remain outstanding. The underlying shares were previously registered but the registration statement is expiring under SEC rules and needs to be refreshed.